Utah Medical Products Inc (UTMD) Reports Mixed 2023 Financial Results
-
Revenue: Decreased by 4% for the full year and 9% for Q4 compared to the previous year.
-
Gross Profit: Dropped by 7% annually and 15% for Q4, with gross profit margins falling below the targeted 60% level.
-
Operating Income: Operating income decreased by 15% for the year and 22% for Q4, impacted by higher overhead costs and litigation expenses.
-
Net Income: Increased by 1% for the year, despite the overall decline in other financial metrics.
-
Earnings Per Share (EPS): EPS saw a 1% increase for the year, benefiting from interest income on cash balances and a lower income tax rate provision.
-
Balance Sheet: Strong with an increase in cash and investments, and a 9% increase in inventories to hedge against supply chain disruptions.
-
Dividends: UTMD paid higher dividends in 2023, with a total of $4,282 ($1.18/share) compared to $3,162 ($0.87/share) in 2022.
On January 30, 2024, Utah Medical Products Inc (NASDAQ:UTMD) released its 8-K filing, disclosing its audited financial performance for the fourth quarter and full year of 2023. The company, known for developing, manufacturing, and distributing medical devices for hospital use, faced a challenging year with a 4% decrease in revenues and a 7% drop in gross profit compared to 2022. However, UTMD managed to report a slight 1% increase in both net income and earnings per share (EPS).
Financial Performance Overview
UTMD's financial results for 2023 were in line with management's projections at the beginning of the year, despite facing headwinds. Total consolidated worldwide sales were $2 million lower due to a $3 million decrease in sales to the company's largest biopharma OEM customer. The company also contended with higher overhead costs due to employee cost-of-living adjustments and increased raw material costs, which contributed to the inability to maintain consistent gross profit margins with the previous year.
Operating income margins were further impacted by unusual litigation expenses related to Filshie clip product liability lawsuits in the U.S. However, interest income on UTMD's cash balances helped bolster earnings before tax (EBT) and net income (NI) margins, leading to the year-over-year increase in net income and EPS.
Income Statement and Balance Sheet Highlights
UTMD's balance sheet remained robust, with cash and investments totaling $92.9 million at the end of 2023, up from $75.1 million the previous year. The company used its cash reserves to increase inventories by $0.8 million, a strategic move to mitigate ongoing supply chain disruptions. Stockholders' equity also increased by $14.1 million despite the payment of stockholder dividends.